SEARCH

SEARCH BY CITATION

References

  • 1
    Wickre CG, Norman DJ, Bennison A, Barry JM, Bennett WM. Postrenal transplant erythrocytosis. A review of 53 patients. Kidney Int 1983; 23: 731737.
  • 2
    Qunibi WY, Barri Y, Devol E, Al-Furayh O, Sheth K, Taher S. Factors predictive of post-transplant erythrocytosis. Kidney Int 1991; 40: 11531159.
  • 3
    Perazella MA, Bia MJ. Posttransplant erythrocytosis: case report and review of newer treatment modalities. J Am Soc Nephrol 1993; 3: 16531659.
  • 4
    Gaston RS, Julian BA, Barker CV, Diethelm AG, Curtis JJ. Enalapril: safe and effective therapy for posttransplant erythrocytosis. Transplant Proc 1993; 25: 10291031.
  • 5
    Danovitch GM, Jamgotchian NJ, Eggena PH et al. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism. Transplantation 1995; 60: 132137.
  • 6
    Midtvedt K, Stokke ES, Hartmann A.Successful long-term treatment of post-transplant erythrocytosis with losartan. Nephrol Dial Transplant 1996; 11: 24952497.
  • 7
    Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100: 23102314.
  • 8
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461470.
  • 9
    Sauron C, Berthoux P, Berthoux F et al. New insights and treatment in posttransplant polycythemia (erythrocytosis) of renal recipients. Transplant Proc 1993; 25: 10321033.
  • 10
    Kessler M, Hestin D, Mayeux D, Mertes PM, Renoult E. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study. Clin Nephrol 1996; 45: 8389.
  • 11
    Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002; 13: 551558.
  • 12
    Carozzi S, Ramello A, Nasini MG et al. Ca++ and 1,25(OH)2D3 regulate in vitro and in vivo the response to human recombinant erythropoietin in CAPD patients. Adv Perit Dial 1990; 6: 312315.
  • 13
    Kelsey SM, Newland AC, Cunningham J et al. Sustained haematological response to high-dose oral alfacalcidol in patients with myelodysplastic syndromes. Lancet 1992; 340: 316317.
  • 14
    Albitar S, Genin R, Fen-Chong M, Serveaux MO, Schohn D, Chuet C. High-dose alfacalcidol improves anaemia in patients on haemodialysis. Nephrol Dial Transplant 1997; 12: 514518.
  • 15
    Torres A, Rodriguez AP, Concepcion MT et al. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998; 13 (Suppl. 3): 9497.
  • 16
    Hercz G, Pei Y, Greenwood C et al. Aplastic osteodystrophy without aluminum: the role of ‘suppressed’ parathyroid function. Kidney Int 1993; 44: 860866.
  • 17
    Miller BA, Cheung JY, Tillotson DL, Hope SM, Scaduto RC Jr. Erythropoietin stimulates a rise in intracellular-free calcium concentration in single BFU-E derived erythroblasts at specific stages of differentiation. Blood 1989; 73: 11881194.
  • 18
    Cheung JY, Zhang XQ, Bokvist K, Tillotson DL, Miller BA. Modulation of calcium channels in human erythroblasts by erythropoietin. Blood 1997; 89: 92100.
  • 19
    Miller BA, Barber DL, Bell LL et al. Identification of the erythropoietin receptor domain required for calcium channel activation. J Biol Chem 1999; 274: 2046520472.
  • 20
    Carozzi S, Grazia Nasini M, Salit M, Cantaluppi A, Nocera A, Valente U. Ca (++) -induced modulation of erythropoiesis in polycythemic transplanted patients. Transplant Proc 1991; 23: 13091311.
  • 21
    Stockenhuber F, Geissler K, Sunder-Plassmann G et al. Erythrocytosis in renal graft recipients due to a direct effect of cyclosporine. Transplant Proc 1989; 21: 15601562.
  • 22
    Klaassen RJ, Van Gelder T, Rischen-Vos J, Deinum J, Man in't Veld AJ, Weimar W. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis. Transplantation 1997; 64: 780782.
  • 23
    Julian BA, Brantley RR, Jr., Barker CV et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9: 11041108.
  • 24
    Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia MJ. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 1995; 26: 495500.
  • 25
    Gupta M, Miller BA, Ahsan N et al. Expression of angiotensin II type I receptor on erythroid progenitors of patients with post transplant erythrocytosis. Transplantation 2000; 70: 11881194.